Supplementary Figures 1 - 7 from Enhancement of Antitumor Immunity in Lung Cancer by Targeting Myeloid-Derived Suppressor Cell Pathways

Authors:
  • ASAnandi Sawant
    Anandi Sawant
  • CSCara C. Schafer
    Cara C. Schafer
  • TJTong Huan Jin
    Tong Huan Jin
  • JZJaroslaw Zmijewski
    Jaroslaw Zmijewski
  • HTHubert M. Tse
    Hubert M. Tse
  • JRJustin Roth
    Justin Roth
  • ZSZhihuan Sun
    Zhihuan Sun
  • GSGene P. Siegal
    Gene P. Siegal
  • VTVictor J. Thannickal
    Victor J. Thannickal
  • SGStefan C. Grant
    Stefan C. Grant
  • SPSelvarangan Ponnazhagan
    Selvarangan Ponnazhagan
  • JDJessy S. Deshane
    Jessy S. Deshane

Abstract
PDF file - 381K, The phenotype of MDSC in the lung and spleen from lung cancer challenged mice (S1); Reduced tumor burden in mice from Gem and SODmim+Gem therapy groups (S2); Combination therapy reduced infiltration of neutrophils but not macrophages in tumor (S3); Combination therapy was efficient in reducing tumor growth in catalase deficient mice by decreasing MDSC infiltration and improving the memory CD8+ T cell response (S4); Persistent memory CD8+ T cell subsets expand following re-encounter with i.v. challenged LLC cells (S5); Adoptively transferred memory cells persist and reduce MDSC infiltration and tumor burden in LLC-rechallenged recipient mice (S6); Adoptively transferred memory cells expand upon encounter with tumor cells (S7).